These are exciting times, with fresh news about research developments appearing every week.
Find out about the latest research news below and also visit our Breaking News in Research page.
Muscular Dystrophy UK is investing £1.2 million into 9 new research projects this year, bringing our total research portfolio to over £10m.Read more
A new study has shown that editing a ‘modifier’ gene can prevent and reverse symptoms in a mouse model of congenital muscular dystrophy type 1A.
Santhera Pharmaceuticals announced that it has started a collaboration with the University of Basel to develop a gene therapy for LAMA2-deficient congenital muscular dystrophy.
Many of the conditions we support at Muscular Dystrophy UK are rare, but few are as rare as LMNA-CMD.
Researchers at University College London (UCL) have developed artificial ‘mini-muscles’ that could speed up testing potential treatments for muscle-wasting conditions.
Santhera announces completion of its omigapil trial in individuals with COL6-related or LAMA2-related congenital muscular dystrophy.
We’re excited to announce a new funding partnership with US-based charity, Cure CMD, to fund research into LMNA congenital muscular dystrophy (LMNA-CMD).
Scientists from the Hospital of Sick Children in Toronto have shown that gene-editing tool CRISPR can correct the underlying genetic mutation in mouse models with MDC1A.
We would like to inform you of a research study for adults with progressive muscle weakness caused by muscular dystrophy or inclusion body myositis (IBM).
We are delighted to be a sponsor of Cure CMD's Scientific & Family Conference, which is taking place in Virginia, USA, over 8-9 July 2017.
The US Food and Drug Administration (FDA) has granted Santhera Pharmaceuticals an award of $246,000 to support its ongoing phase 1 clinical trial testing Omigapil in children with